These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9433338)

  • 61. Plasma haloperidol levels: clinical response and fancy mathematics.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
    [No Abstract]   [Full Text] [Related]  

  • 62. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
    Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The relationship between haloperidol blood levels and clinical responses.
    Itoh H; Yagi G; Fujii Y; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):285-92. PubMed ID: 6539935
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The interpretation of plasma haloperidol concentrations.
    Kirch DG; Bigelow LB; Wyatt RJ
    Arch Gen Psychiatry; 1985 Aug; 42(8):838-40. PubMed ID: 4015329
    [No Abstract]   [Full Text] [Related]  

  • 65. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
    Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
    Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate.
    Altamura AC; Tacchini GL; Maes M
    Eur Neuropsychopharmacol; 1995; 5 Suppl():55-8. PubMed ID: 8775759
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
    Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y
    J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes.
    Meyer JM
    CNS Spectr; 2014 Oct; 19(5):432-8. PubMed ID: 24865765
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
    Yao JK; van Kammen DP
    Schizophr Res; 1994 Feb; 11(3):209-16. PubMed ID: 8193060
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
    Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
    J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Haloperidol plasma concentrations in Taiwanese psychiatric patients.
    Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH
    J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.
    Chang WH; Hwu HG; Lane HY; Lin SK; Chen TY; Chen H; Wei HL; Lin WL; Lin HN
    Psychiatry Res; 1991 Sep; 38(3):215-25. PubMed ID: 1754634
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
    Libiger J; Czobor P; Volavka J
    Psychiatry Res; 1994 May; 52(2):107-14. PubMed ID: 7972567
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical response and plasma haloperidol levels in schizophrenia.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    Psychopharmacology (Berl); 1983; 81(4):354-6. PubMed ID: 6419263
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Plasma drug level and clinical response.
    Cooper TB; Volavka J; Czobor P
    J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036
    [No Abstract]   [Full Text] [Related]  

  • 79. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences.
    Altamura C; Mauri M; Cavallaro R; Colacurcio F; Gorni A; Bareggi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):689-94. PubMed ID: 3222450
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Haloperidol plasma levels and clinical response in paranoid schizophrenics.
    Linkowski P; Hubain P; von Frenckell R; Mendlewicz J
    Eur Arch Psychiatry Neurol Sci; 1984; 234(4):231-6. PubMed ID: 6526061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.